Literature DB >> 11087252

Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow.

T Suwa1, J C Hogg, D English, S F Van Eeden.   

Abstract

Recombinant human interleukin-6 (IL-6) causes both a thrombocytosis and leukocytosis. The thrombocytosis is caused by an accelerating thrombocytopoiesis, but the mechanism of the leukocytosis is unknown. This study was designed to determine the relative contributions of marrow stimulation and intravascular demargination to the IL-6 induced neutrophilia. IL-6 (2 microgram/kg), administered intravenously to rabbits, caused a biphasic neutrophilia with an initial peak at 3 h and a second peak at 9 h. Using the thymidine analog 5'-bromo-2'-deoxyuridine (BrdU) to label dividing polymorphonuclear leukocytes (PMNs) in the bone marrow, we showed that IL-6 treatment mobilizes PMNs from the marginated pool into the circulating pool at 2-6 h with a decrease in L-selectin expression on PMNs and also accelerates the release of PMNs from the postmitotic pool in the bone marrow at 12-24 h. We have concluded that IL-6 causes a biphasic neutrophilia wherein the first peak results from the mobilization of PMNs into the circulating pool from the marginated pool and the second peak results from an accelerated bone marrow release of PMNs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087252     DOI: 10.1152/ajpheart.2000.279.6.H2954

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  47 in total

Review 1.  Mechanistic models for myelosuppression.

Authors:  Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

2.  Does prolonged cycling of moderate intensity affect immune cell function?

Authors:  J Scharhag; T Meyer; H H W Gabriel; B Schlick; O Faude; W Kindermann
Journal:  Br J Sports Med       Date:  2005-03       Impact factor: 13.800

Review 3.  Neutrophils: key mediators of tumour angiogenesis.

Authors:  Simon Tazzyman; Claire E Lewis; Craig Murdoch
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

4.  Color of meconium and interleukin-6.

Authors:  Raquel Silva-Bravo; Gabriel Mayoral-Andrade; Edgar Zenteno; Pedro Hernandez; Ruth Martínez-Cruz; Laura Perez-Campos Mayoral; Sergio Aguilar-Ruiz; Alberto Paz-Pacheco; Romeo Zarate-Aspiros; Magdalena López-Bravo; Yuri Roldan-Aragon; Eduardo Pérez-Campos
Journal:  Indian J Pediatr       Date:  2011-05-28       Impact factor: 1.967

5.  Association of TNFSF8 polymorphisms with peripheral neutrophil count.

Authors:  Adelaide M Arruda-Olson; Véronique L Roger; High S Chai; Mariza de Andrade; Brooke L Fridley; Julie M Cunningham; Sherine E Gabriel; Suzette J Bielinski
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

6.  A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers.

Authors:  Yoichiro Ogama; Tomoko Mineyama; Asuka Yamamoto; Margaret Woo; Naomi Shimada; Taro Amagasaki; Kazuto Natsume
Journal:  Int J Hematol       Date:  2013-02-05       Impact factor: 2.490

7.  Phenotypic and functional analysis of human T lymphocytes in early second- and third-trimester fetuses.

Authors:  Y Zhao; Z-P Dai; P Lv; X-M Gao
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 8.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Leukocyte Count versus C-Reactive Protein Levels in Obese Portuguese Patients Aged 6-12 Years Old.

Authors:  Henrique Nascimento; Susana Rocha; Carla Rego; Helena Ferreira Mansilha; Alexandre Quintanilha; Alice Santos-Silva; Luís Belo
Journal:  Open Biochem J       Date:  2010-06-10

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.